General counsel

ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio

Retrieved on: 
Friday, April 19, 2024
Adenosine, IP, General counsel, European Patent Convention, RNA, AON, Oligonucleotide, Deamination, Science, Patent, Ribose, Therapy, ProQR, ADAR, EPO, Vaccine

This patent is part of ProQR’s intellectual property estate surrounding its Axiomer RNA editing platform and the current generation of its molecules.

Key Points: 
  • This patent is part of ProQR’s intellectual property estate surrounding its Axiomer RNA editing platform and the current generation of its molecules.
  • Since then, ProQR has filed multiple additional patent applications on further improvements to form a leading patent estate that supports ProQR’s ADAR-mediated RNA editing platform Axiomer.
  • Today ProQR has extensive patent protection related to the Axiomer RNA editing platform, including 15 published patent families, that currently comprise a total of 28 patents.
  • Beyond this, ProQR has several unpublished patent applications and continuously invests in expanding its IP estate around ADAR-mediated RNA editing.

OptimizeRx Releases 2024 Environmental, Social, and Governance (ESG) Report

Retrieved on: 
Thursday, April 18, 2024
DEI, Prosperity, Parity, Social, General counsel, Policy, Omnichannel, Biophysical environment, Environment, Patient, Mental health, ESG, Senior, Workforce, Fruit, Organization, DAAP

WALTHAM, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, has published its Environmental, Social and Governance (ESG) report for 2024.

Key Points: 
  • WALTHAM, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, has published its Environmental, Social and Governance (ESG) report for 2024.
  • Our ESG report uses a standardized framework developed by the World Economic Forum, which includes 21 core metrics across four categories: Governance, Planet, People and Prosperity.
  • OptimizeRx intends to review ESG progress quarterly, and to update the ESG report periodically.
  • To read OptimizeRx’s full ESG report, please visit the Company’s governance page on its website or click here .

ibex’s Christy O’Connor Named Among Top 50 Chief Legal Officers

Retrieved on: 
Tuesday, April 16, 2024
Law, University, International law, Mentorship, Woman, General counsel, Ibex, University School, Human, BPO, SourceHOV, Admire, Kansas, Organization

WASHINGTON, April 16, 2024 (GLOBE NEWSWIRE) -- ibex (NASDAQ: IBEX), a leading global provider of business process outsourcing (BPO) and customer engagement technology solutions, today announced that Christy O’Connor has been named among the Top 50 Chief Legal Officers of 2024 by Women We Admire.

Key Points: 
  • WASHINGTON, April 16, 2024 (GLOBE NEWSWIRE) -- ibex (NASDAQ: IBEX), a leading global provider of business process outsourcing (BPO) and customer engagement technology solutions, today announced that Christy O’Connor has been named among the Top 50 Chief Legal Officers of 2024 by Women We Admire.
  • “Christy’s inclusion on the list of Top 50 Chief Legal Officers underscores her exceptional leadership and unwavering commitment to excellence,” said Bob Dechant, CEO of ibex.
  • Women We Admire’s list of Top 50 Chief Legal Officers honors leaders that serve some of the world’s most well-known companies and organizations.
  • Prior to ibex, she was Chief Legal Officer at Alorica, a provider of customer management outsourcing solutions.

Asurint Hosts Webinar on Key Updates to Employment Law, Drug Testing, Legal Compliance for Background Screening

Retrieved on: 
Thursday, April 11, 2024
Human resources, PBSA, Employment, EDT, FCRA, General counsel, Past, Q&A, Nursing

Cleveland, Ohio, April 11, 2024 (GLOBE NEWSWIRE) -- Asurint, a leading background screening solutions provider, announced it will be holding a free online webinar, “Keeping Up with Compliance: Legal Updates You Should Know,” on Thursday, April 25th at 12 p.m. EDT.

Key Points: 
  • Cleveland, Ohio, April 11, 2024 (GLOBE NEWSWIRE) -- Asurint, a leading background screening solutions provider, announced it will be holding a free online webinar, “Keeping Up with Compliance: Legal Updates You Should Know,” on Thursday, April 25th at 12 p.m. EDT.
  • The legal landscape of employment, background screening, and drug testing laws continues to evolve.
  • “Keeping Up with Compliance” provides updates on key impacts to employers and Human Resources professionals tasked with performing background checks and drug testing across many industries.
  • Presenter Kelly Uebel has served as General Counsel for Asurint since 2017 and has worked in the background screening industry since 2011.

OCC Announces Director Elections at Annual Stockholder Meeting

Retrieved on: 
Wednesday, May 1, 2024
Banking, Fintech, Professional Services, Finance, Credit Suisse, New York Stock Exchange, Intercontinental Exchange, Cboe Global Markets, General counsel, Product innovation, Exchange, Founding, Senior, Multimedia, OCC

In addition, OCC announced the election of Andrej Bolkovic , OCC Chief Executive Officer, as the Management Director.

Key Points: 
  • In addition, OCC announced the election of Andrej Bolkovic , OCC Chief Executive Officer, as the Management Director.
  • The vote took place during OCC’s annual stockholder meeting on April 19, 2024.
  • The following Director was unanimously elected as a Class III Public Director for the term ending in 2027:
    Dr. Thomas R. Cardello , Founding Member, Venice Financial Management, LLC.
  • “The high caliber of leadership represented on our Board demonstrates that OCC has the capabilities necessary to achieve our objectives while fulfilling our critical obligations.”

STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel

Retrieved on: 
Wednesday, May 1, 2024
Optical, Health, Surgery, Medical Devices, Corporation, Science, Medtech, Near-sightedness, Law, University, Presbyopia, American Tower, Believer, EVO, General counsel, OTC, Marketing, Commerce, Johnson & Johnson, STAAR, Surgeon, University School, Business, Partner (business rank), CareFusion, Contact, Duke University, NuVasive, Senior, Patient, Multimedia, Global marketing, Emory University, Associate, Astigmatism, Economics, Nate, Growth, Engineering, Management

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced Nancy Sabin has been named Chief Marketing Officer and Nathaniel Sisitsky has been named General Counsel.

Key Points: 
  • STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced Nancy Sabin has been named Chief Marketing Officer and Nathaniel Sisitsky has been named General Counsel.
  • View the full release here: https://www.businesswire.com/news/home/20240501408389/en/
    “We are thrilled to strengthen the STAAR team with the addition of Nancy and Nate, two seasoned executives with extensive senior leadership experience.
  • “Nancy is a perfect fit for the newly created Chief Marketing Officer position and will be critical to driving our brand awareness and innovation globally.
  • “I am thrilled to join the STAAR leadership team at a time of significant opportunity and growth for our vision correction lenses,” said Nate Sisitsky.

Metals Acquisition Limited Announces Appointment of Leanne Heywood to the Board of Directors

Retrieved on: 
Wednesday, May 1, 2024
Mining, Minerals, Natural Resources, Lithium, Remuneration, Defense, CPA Australia, Risk, General counsel, Commercial, Accounting, FCPA, ASX, MWY, Melbourne Business School, MAC, Acquisition, Snowy Hydro, Woman, Management

Metals Acquisition Limited ARBN 671 963 198 (NYSE: MTAL; ASX: MAC), a private limited company incorporated under the laws of Jersey, Channel Islands (“MAC” or the “Company”) is pleased to announce the appointment of Ms. Leanne Heywood as a Non-Executive Director to the Company’s Board of Directors, effective 1 May 2024.

Key Points: 
  • Metals Acquisition Limited ARBN 671 963 198 (NYSE: MTAL; ASX: MAC), a private limited company incorporated under the laws of Jersey, Channel Islands (“MAC” or the “Company”) is pleased to announce the appointment of Ms. Leanne Heywood as a Non-Executive Director to the Company’s Board of Directors, effective 1 May 2024.
  • Ms Heywood received the 2021 Medal of the Order of Australia and was named 2019 NSW Business Women of the Year.
  • Patrice Merrin, Chair of the Board of MAC commented, “We are pleased to welcome Leanne to the Board.
  • Leanne brings profound experience in audit, risk, people and remuneration which will further complement the board.

Cranfill Sumner Launches MBM in Washington, D.C., with Partners Patrick Mincey and Stephen Bell and Christina Zaroulis Milnor, Former Assistant Secretary of the SEC

Retrieved on: 
Wednesday, May 1, 2024
Consulting, Professional Services, Legal, United Nations, University, General counsel, Truth Social, Financial Crimes Enforcement Network, Social media, Lawyer, Comptroller, Kremlin, Vladimir Putin, Security (finance), False Claims Act, Intelligence, B.A, MBM, DOJ, Bell, Multimedia, Assistant, Currency, Government, Harvard University, PDVSA

The new group, Mincey Bell Milnor (MBM) will focus on white collar, regulatory enforcement, high-stakes civil litigation, and representation of whistleblowers before federal agencies.

Key Points: 
  • The new group, Mincey Bell Milnor (MBM) will focus on white collar, regulatory enforcement, high-stakes civil litigation, and representation of whistleblowers before federal agencies.
  • “With MBM, we have landed a prominent government official, just exiting the SEC, paired with two nationally known white collar litigators.
  • We set it up this way so these lawyers could have the visibility of a boutique group with the platform of our larger firm.
  • We plan to continue to grow the practice from here.”
    Milnor has held significant roles at the SEC for more than a decade.

ASA Gold and Precious Metals Board Shareholders Elect Saba Capital Nominees to the Fund’s Board of Directors

Retrieved on: 
Wednesday, May 1, 2024
Banking, Asset Management, Professional Services, Finance, General counsel, Annual general meeting, NAV, Boaz Weinstein, Fund, Gold, ASA

Saba Capital Management, L.P. (“Saba” or “we”), the largest common shareholder of ASA Gold and Precious Metals Limited (NYSE: ASA) (“ASA” or the “Fund”), today commented on the outcome of the Fund’s 2024 Annual Meeting of Shareholders (the “Annual Meeting”).

Key Points: 
  • Saba Capital Management, L.P. (“Saba” or “we”), the largest common shareholder of ASA Gold and Precious Metals Limited (NYSE: ASA) (“ASA” or the “Fund”), today commented on the outcome of the Fund’s 2024 Annual Meeting of Shareholders (the “Annual Meeting”).
  • Based on preliminary results of the Annual Meeting, shareholders voted to elect Saba nominees Ketu Desai and Paul Kazarian to ASA’s Board of Directors (the “Board”).
  • No other nominee, including the incumbent directors sitting for reelection, received a majority of votes cast required under the bylaws.
  • Saba’s directors will take action to improve shareholder returns, rebuild trust and protect shareholders’ rights.”

Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer

Retrieved on: 
Tuesday, April 30, 2024
Professional Services, Health, Infectious Diseases, Legal, Clinical Trials, Pharmaceutical, Biotechnology, Corporation, University, General counsel, Eli Lilly, ARIAD Pharmaceuticals, Virology, Hall, Civil Service (United Kingdom), B.A, Patient, Acquisition, White, Caregiver, Proteon Therapeutics, Multimedia, Intellectual property, Notre Dame Law School, Medication, Therapy, Cubist Pharmaceuticals, Growth, Pharmaceutical industry

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the appointment of Matthew P. Kowalsky, J.D., as Chief Legal Officer.

Key Points: 
  • Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the appointment of Matthew P. Kowalsky, J.D., as Chief Legal Officer.
  • In this role, he will lead all legal and compliance activities for Enanta, as well as provide strategic guidance and corporate governance oversight.
  • Prior to joining Enanta, Mr. Kowalsky held legal and operational roles of increasing responsibility at Sigilon Therapeutics, Inc., until its acquisition by Eli Lilly in 2023.
  • Most recently, he served as the Chief of Staff and Chief Legal and Administrative Officer of Sigilon, which he joined in 2019 as its General Counsel and Corporate Secretary.